Uremic Pruritus Clinical Trial
Official title:
The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Verified date | September 2010 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: Department of Health |
Study type | Interventional |
The purpose of this study was to confirm the efficacy of NB UVB phototherapy in alleviating uremic pruritus and investigate the association between improvement of pruritus and change of serum parameters, including routine biochemical data, immune profile and dialysis adequacy.
Status | Completed |
Enrollment | 21 |
Est. completion date | July 2009 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Chronic kidney disease with moderate to severe uremic pruritus for longer than 2 months Exclusion Criteria: - pregnancy history of photosensitivity photo-aggravated disease |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Taiwan | Department of dermatology, National Taiwan Univeristy Hospital Yun-Lin branch | Douliou City | Yunlin County |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Visual Analogue Scale (VAS) Score for Pruritus | a VAS is a horizontal line, 100 mm in length. The patient marks on the line the point that they feel represents their perception of their pruritus. 0 (no pruritus) - 10 (most severe pruritus) The investigator will determine the pruritic intensity at baseline, every 3 sessions by VAS score, and by detailed questionnaire at baseline and after 18 sessions |
VAS score at baseline and after 6 -week phototherapy | No |
Secondary | Detailed Questionnaire at Baseline and After 18 Sessions | at baseline and after 18 sessions | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04728984 -
A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet
|
Phase 3 | |
Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Terminated |
NCT01660243 -
Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
|
Phase 2 | |
Completed |
NCT06159686 -
The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05525234 -
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
|
Phase 4 | |
Completed |
NCT03002233 -
TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
|
Phase 1 | |
Completed |
NCT03998163 -
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
Active, not recruiting |
NCT05885737 -
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
|
Phase 3 | |
Recruiting |
NCT04393675 -
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03576235 -
Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients
|
N/A | |
Completed |
NCT05575193 -
Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis
|
N/A | |
Completed |
NCT02858726 -
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT02143648 -
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Recruiting |
NCT06446310 -
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
|
Phase 3 | |
Completed |
NCT03758079 -
Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus
|
Phase 4 | |
Completed |
NCT02229929 -
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
|
Phase 2 | |
Completed |
NCT04639674 -
AST-120 in Hemodialysis Patients With Uremic Pruritus
|
Phase 4 | |
Completed |
NCT03636269 -
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
Not yet recruiting |
NCT06466421 -
Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis
|
Phase 4 | |
Completed |
NCT04711603 -
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
|
Phase 3 |